[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-acute-pancreatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-acute-pancreatitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,50,79,103,138,162,183,211,233,262,286,310],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100639253","phase-4-glp-1-agonists-for-prevention-of-recurrent-hypertriglyceridemic-acute-pancreatitis-100639253",false,"NCT07617155","GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis","Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence: Protocol for a Randomized Clinical Trial","RECAP-GLP1","Inclusion Criteria\n\n* Age ≥ 18 years old\n* Previous diagnosis of index HTG-AP (defined as AP with serum TG \\>1000 mg\u002FdL or a serum TG level of 500-1000 mg\u002FdL accompanied by chylous serum)36-38\n* Having HTG as the exclusive cause of AP\n* Time from discharge of index HTG-AP to recruitment between 4 weeks to 3 months, without AP-related symptoms between discharge and recruitment\n* Expression of the willingness to comply with lifestyle modification during the study period.\n* Clinically stable at the time of inclusion\n* The ability to understand the trial and completing it, as evaluated by the investigators.\n* Patients who may get pregnant should ensure using contraceptives for 20 months after inclusion Exclusion Criteria\n* History of malignancy in past 5 years\n* History of hypothyroidism, nephrotic syndrome, Cushing's syndrome or AIDS\n* History of chronic pancreatitis or pancreatic neoplasm\n* History of severe cardiovascular and pulmonary diseases, such as heart failure, coronary heart disease and chronic obstructive pulmonary disease.\n* Severe renal deficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin)\n* Severe hepatic deficiency (Child-Pugh Class B or C)\n* Previous pancreatic surgery\n* Recurrent AP due to pancreatic diverticulum\n* Recurrent AP due to known genetic mutations (eg. CFTR)\n* Personal or family history of medullary thyroid carcinoma (MTC)\n* Current or prior diagnosis or suspected diagnosis of multiple endocrine neoplasia type 2 (MEN2)\n* Serious hypersensitivity reaction to semaglutide or any of the excipients in the investigational drug or placebo\n* Pregnancy\n* Breast-feeding","ALL","18 Years",{"count":20,"type":21},396,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is associated with a high risk of recurrence despite standard lipid-lowering therapy and lifestyle modification. The goal of this clinical trial is to evaluate whether GLP-1 receptor agonist therapy can reduce the recurrence of HTG-AP in adults with a history of HTG-AP and hypertriglyceridemia.\n\nThe main questions this study aims to answer are:\n\n* Whether GLP-1 receptor agonist therapy reduces the recurrence rate of HTG-AP.\n* Whether GLP-1 receptor agonist therapy improves triglyceride control, body weight, and metabolic parameters.\n* Whether GLP-1 receptor agonist therapy is safe and well tolerated in this patient population.\n\nResearchers will compare GLP-1 receptor agonist therapy plus standard care with standard care alone to determine whether GLP-1 receptor agonist therapy provides additional benefit in preventing recurrent HTG-AP.\n\nParticipants will:\n\n* Receive either GLP-1 receptor agonist therapy plus standard care or standard care alone.\n* Undergo regular clinical follow-up visits and laboratory assessments.\n* Receive monitoring of triglyceride levels, recurrence events, metabolic outcomes, and adverse events during the study period.",[27,28,29,30],"Hypertriglyceridemia Induced Acute Pancreatitis","Recurrent Acute Pancreatitis","Pancreatitis Relapsing","Hypertriglyceridemia",[32,33,34,35,36],"hypertriglyceridemia-induced acute pancreatitis","recurrent acute pancreatitis","semaglutide","GLP-1 receptor agonist","pancreatitis prevention","NOT_YET_RECRUITING","2026-05-28",{"date":40,"type":41},"2026-06-01","ACTUAL",{"date":43,"type":21},"2026-09",{"date":45,"type":21},"2028-12",{"name":47,"class":48},"Peking Union Medical College Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100625127","phase-4-malabsorption-blood-test-mbt-to-determine-exocrine-pancreatic-function-and-related-quality-of-life-in-chronic-pancreatitis-100625127","NCT07418593","Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis","MBT","Inclusion Criteria\n\n* ≥ 18 years of age\n* RAP (≥ 2 documented lifetime attacks with ≥ 2 of 3 acute pancreatitis criteria) OR Chronic pancreatitis (Cambridge I or II with documented history of AP OR Cambridge III or IV criteria)\n* Fecal elastase ≥ 50 within the preceding 12 months\n\nExclusion Criteria\n\n* Allergy\u002FIntolerance to PERT\u002FMBT\n* Taking medications that alter fat absorption or that supplement the fatty acids being studied (e.g. orlistat, ursodeoxycholic acid, Fatty-15 fatty acid supplement etc.)\n* Taking GLP-1 Receptor Agonist therapy\n* Fecal elastase \\\u003C50 within preceding 12 months OR pre-existing diagnosis of severe Exocrine Pancreatic Insufficiency, or ongoing steatorrhea\n* Receiving Pancreatic Enzyme Replacement Therapy for \\> 5 days within the preceding 30 days\n* Acute Pancreatitis attack (documented and meeting at least 2 of 3 criteria) within the preceding 90 days\n* History of pancreatic resection or underlying malabsorptive disease\n* Pregnant or Breast Feeding\n* Other significant medical condition as judged by Principal Investigator",{"count":58,"type":21},80,[24],"This project uses the Malabsorption Blood Test (MBT) to identify patients with recurrent acute or chronic pancreatitis who have mild to moderate exocrine pancreatic insufficiency. A subgroup of patients who have response to pancreatic enzyme replacement therapy will enter a randomized, placebo-controlled pilot clinical trial for 8 weeks to identify improvements in quality of life (QOL).",[62,28,63],"Chronic Pancreatitis","Exocrine Pancreatic Insufficiency",[65,66,67,63],"Malabsorption Blood Test(MBT)","Chronic pancreatitis","Recurrent Acute pancreatitis","RECRUITING","2026-04-21",{"date":71,"type":41},"2026-04-27",{"date":73,"type":41},"2026-04-20",{"date":75,"type":21},"2028-09",{"name":77,"class":48},"Anna Evans Phillips",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100566161","biospecimen-collection-to-identify-gene-mutations-for-high-risk-pancreatic-cancer-in-pediatric-patients-insppire-2-study-100566161","NCT06651580","Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study","Pediatric Longitudinal Cohort Study of Chronic Pancreatitis (INSPPIRE 2)","Inclusion Criteria:\n\n* All subjects\u002Fparents must sign an informed consent and\u002For assent indicating that they are aware of the investigational nature of this study\n* Subjects\u002Fparents must have signed an authorization for the release of their or their child's protected health information\n* All children must be under 18 years of age at the time of enrollment\n* All children providing samples should fit the ARP or CP inclusion criteria defined below:\n\n  * Acute pancreatitis (AP): AP is defined as requiring 2 of the following:\n\n    * Abdominal pain compatible with AP\n    * Serum amylase and\u002For lipase values \\>= 3 times upper limits of normal\n    * Imaging findings of AP, such as gland enlargement, acute inflammatory changes, and fluid collections\n  * ARP is defined as: At least 2 episodes of acute pancreatitis with complete resolution of pain and a \\>= 1 month pain-free interval between episodes\n  * Chronic Pancreatitis:\n\n    * Children with at least:\n\n      * One irreversible structural change in the pancreas with or without abdominal pain +\u002F- exocrine pancreatic insufficiency +\u002F- diabetes\n\n        * Irreversible structural changes:\n\n          * Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound \\[abd US\\], magnetic resonance imaging\u002Fmagnetic resonance cholangiopancreatography \\[MRI\u002FMRCP\\], computerized tomography \\[CT\\], endoscopic retrograde cholangiopancreatography \\[ERCP\\], endoscopic US \\[EUS\\])\n          * Ductal obstruction or stricture\u002Fdilatation\u002Firregularities that are persistent (for \\>= 2 months) on any imaging\n          * Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities alone are not diagnostic findings for CP\n          * Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages)\n\nExclusion Criteria:\n\n* Subjects must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the subject's ability to tolerate study interventions","17 Years",{"count":88,"type":21},1600,"OBSERVATIONAL","This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer.",[62,92,28],"Exocrine Pancreas Carcinoma","2026-03-03",{"date":95,"type":41},"2026-03-04",{"date":97,"type":41},"2021-04-01",{"date":99,"type":21},"2027-02-02",{"name":101,"class":48},"M.D. Anderson Cancer Center",26,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":49},"100627365","phase-1-soy-tomato-juice-to-improve-outcomes-in-pancreatitis-100627365","NCT07447687","Soy Tomato Juice to Improve Outcomes in Pancreatitis","Soy Tomato Juice to Improve Outcomes in Pancreatitis (the STOP Trial): a Phase 1\u002F2 Single Arm Trial","STOP","Inclusion Criteria:\n\n* Diagnosis of definite chronic pancreatitis (CP) or recurrent acute pancreatitis (RAP)\n* Patients should be able to fully understand and participate in all aspects of the study\n\nExclusion Criteria:\n\n* Episode of acute pancreatitis, hospitalization, or endoscopic\u002Fsurgical intervention within 30 days of enrollment\n* Chronic, daily use of systemic immunomodulatory medication for any indication\n* Previous allergic reaction to soy or tomato products\n* Known pregnancy","80 Years",{"count":113,"type":21},35,[115,116],"PHASE1","PHASE2","This goal of this clinical trial is to see if people with recurrent acute pancreatitis or chronic pancreatitis can tolerate and regularly drink a tomato juice beverage. Researchers will also measure inflammation and ask participants to report how they feel. Everyone in the study will receive the tomato juice drink, and both participants and researchers will know what is being taken. The investigators expect the drink will be well tolerated, may lower inflammation, and may improve participant-reported symptoms and quality of life.",[28,62],[120,121,122,123,124,125,126,127,128,129,130],"Soy","Tomato","Dietary Intervention","abdominal pain","inflammation","lycopene","soy isoflavones","anti-inflammatory diet","medical nutrition","diet","Ohio State University","2026-02-26",{"date":93,"type":41},{"date":134,"type":21},"2026-02",{"date":136,"type":21},"2028-06",{"name":130,"class":48},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100498547","early-phase-1-simvastatin-treatment-to-improve-patient-reported-outcomes-in-patients-with-chronic-pancreatitis-100498547","NCT05771675","Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis","SMV in CP","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged 18-75 at time of enrollment\n4. Diagnosis of Recurrent Acute or Chronic Pancreatitis not attributable to gallstones (i.e., suspected or definite biliary etiology), medications, trauma or autoimmune pancreatitis. For CP, imaging studies that can be used for diagnosis classification using Cambridge criteria46,47.\n5. Ability to take oral medication and be willing to adhere to the dosing regimen.\n6. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional one month after administration of study medication.\n7. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional one month after administration of study medication.\n8. No prior pancreatic surgery\n9. No current statin use for 6 months.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. History of autoimmune, medication caused or traumatic pancreatitis.\n3. Primary pancreatic tumors - pancreatic ductal adenocarcinoma, suspected cystic neoplasm (\\>1 cm. in size or main duct involvement), neuroendocrine tumors, and other uncommon tumors.\n4. Pancreatic metastasis from other malignancies.\n5. History of solid organ transplant, HIV\u002FAIDS.\n6. Known isolated pancreatic exocrine insufficiency (i.e.., in the absence of any eligible inclusion criteria).\n7. Subjects required to take itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone, gemfibrozil, cyclosporine, danazol, amiodarone, or verapamil for other clinical indications.\n8. Current simvastatin use within the past 6 months.\n9. Participants must not have medical or psychiatric illnesses or ongoing substance abuse that in the investigator's opinion would compromise their ability to tolerate study interventions or participate in longitudinal follow up.\n10. Patients with active liver disease.\n11. Known Pregnancy. All participants of childbearing potential, except if post-menopausal (i.e., no menses for ≥2 years) or had a hysterectomy, bilateral tubal ligation\u002Fclip (surgical sterilization) or surgical removal of both the ovaries), must have a negative urine or serum B-HCG pregnancy test documented within 2 days prior to any endoscopic or radiologic procedures done for research purposes. Any standard of care tests will follow institutional policies regarding pregnancy test.\n12. Currently incarcerated.\n13. Inability to comply with study activities.","75 Years",{"count":147,"type":21},90,[149],"EARLY_PHASE1","The purpose of this pilot study to examine the feasibility and acceptability of simvastatin in adults with Recurrent Acute Pancreatitis (RAP) and Chronic Pancreatitis (CP).",[28,62],"2026-02-25",{"date":154,"type":41},"2026-02-27",{"date":156,"type":41},"2024-10-24",{"date":158,"type":21},"2027-06",{"name":160,"class":48},"Cedars-Sinai Medical Center",5,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":49},"100474127","phase-1-a-surgical-procedure-total-pancreatectomy-with-a-transplant-procedure-islet-cell-autotransplantation-for-the-treatment-of-chronic-pancreatitis-and-benign-pancreatic-tumors-100474127","NCT05453851","A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors","Total Pancreatectomy With Islet Cell Autotransplantation in Patients With Benign Pancreatic Neoplasms: A Pilot Study","Inclusion Criteria:\n\n* Participant or legally authorized representative (LAR) must provide written informed consent before any study-specific procedures or interventions are performed\n* Age\\>= 18 years. Both men and women and members of all races and ethnic groups will be included. Gender-nonconforming and gender-fluid individuals as members of the general population will also be included\n* Participants must have adequate islet cell function (non-diabetic or C-peptide positive)\n* Participants must be indicated for total surgical resection of the pancreas for chronic pancreatitis-associated pain meeting eligibility criteria for TPIAT per University of Minnesota Criteria as defined by all of the following\n\n  * Chronic abdominal pain of \\> 6-month duration with at least one of the following:\n\n    * Pancreatic calcification on computed tomography (CT) scan\n    * At least two of the following:\n\n      * Definite of suggestive diagnosis of chronic pancreatitis on endoscopic ultrasound\n      * Ductal or parenchymal abnormalities compatible with chronic pancreatitis on secretin magnetic resonance cholangiopancreatography\n      * Abnormal endoscopic pancreatic function tests (peak HCO2 \\\u003C 80mM)\n    * Histopathology confirmed diagnosis of chronic pancreatitis\n    * Compatible clinical history and documented hereditary pancreatitis gene mutation OR\n    * History of recurrent acute pancreatitis (more than one episode of characteristic pain associated with imaging diagnostic of acute pancreatitis and\u002For elevated serum amylase or lipase \\> 3 times upper limit of normal\n  * At least one of the following:\n\n    * Daily narcotic dependence\n    * Pain resulting in impaired quality of life, which may include: inability to attend school, recurrent hospitalizations, or inability to participate in usual, age-appropriate activities.\n  * Complete evaluation with no reversible cause of pancreatitis present or untreated\n  * Failure to respond to maximal medical and endoscopic therapy\n* If clinical, radiologic, or biochemical evidence suggestive of cirrhosis or metabolic syndrome (defined in exclusion criteria), the participant has undergone hepatology evaluation and been exonerated of a cirrhosis diagnosis or otherwise deemed to be at low hepatic risk from IAT\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 1\n* Life expectancy of greater than 2 years\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with a prior or active non-pancreatic malignancy are eligible for this trial\n* Invasive abdominal surgical procedures such as pancreatectomy have the known potential to cause pregnancy loss. For this reason, persons of reproductive potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to undergoing pancreatectomy and IAT. Should a participant become pregnant or suspect a pregnancy prior to planned pancreatectomy and IAT, the participant should inform their treating physician immediately\n\nExclusion Criteria:\n\n* Prior allogenic or autologous islet cell transplantation\n* Underlying liver disease, unless participant has undergone hepatology consultation to evaluate hepatic risk from IAT and been deemed low-risk, including:\n\n  * Cirrhosis, defined by either\n\n    * Pathologic diagnosis of cirrhosis OR\n    * Diagnosis of cirrhosis by hepatology following evaluation prompted by clinical, radiographic, or biochemical evidence of cirrhosis\n  * Hepatic steatosis as defined by pathologic examination of the liver or liver magnetic resonance imaging in the absence of pathologic evidence\n* Use of any systemically absorbed steroid (e.g., prednisone but not budesonide) within the prior month\n* Untreated malignancy of a non-pancreatic primary\n* Cytology or biopsy of a pancreatic neoplasm diagnostic for malignancy prior to the time of IAT\n* A pancreatic neoplasm deemed to be at high risk for harboring occult malignancy as assessed by the multi-disciplinary pancreas tumor board and multi-disciplinary chronic pancreatitis conference after comprehensive evaluation of relevant clinical, radiographic, pathologic, and serologic data. Features of high-risk neoplasms include the following, however the below items are not to be taken as absolute contraindications to TPIAT:\n\n  * Obstructive jaundice in a patient with a pancreatic cystic neoplasm in the head of the pancreas\n  * Enhancing mural nodule of any size\n  * Main pancreatic duct \\>= 5mm\n  * Acute pancreatitis with cystic lesion as the only potentially identifiable cause\n  * Cyst \\>= 3cm, if lesion is a mucinous neoplasm\n  * Thickened\u002Fenhancing cyst walls\n  * Abrupt change in caliber of pancreatic duct with distal pancreatic atrophy on imaging\n  * Celiac\u002Fportal lymphadenopathy\n  * Serum CA19-9 above the institutional upper limit of normal\n  * Pancreatic cyst growth rate \\>= 5mm every 2 years\n  * Cytology suspicious for malignancy\n  * Clinical suspicion for main duct involvement based on imaging\n* Evidence of metabolic syndrome, as defined by any 3 of the below features, unless the participant has undergone hepatology consultation to evaluate hepatic risk from IAT and been deemed low-risk:\n\n  * Waist circumference more than 40 inches in men and 35 inches in women\n  * Elevated triglycerides 150 milligrams per deciliter of blood (mg\u002FdL) or greater\n  * Reduced high-density lipoprotein cholesterol (HDL) less than 40 mg\u002FdL in men or less than 50 mg\u002FdL in women\n  * Elevated fasting glucose of 100 mg\u002FdL or greater\n  * Blood pressure values of systolic 130 mmHg or higher and\u002For diastolic 85 mmHg or higher\n* Multifocal or large pancreatic neoplasms such that an insufficient volume of remnant pancreas would remain for the patient to benefit from IAT following resection of the neoplasms in the opinion of the multi-disciplinary chronic pancreatitis board\n* History of allergic reaction to human albumin preparations\n* Demonstrated medical non-compliance\n* Patient unsafe to undergo the required pancreatectomy procedure in the opinion of the attending surgeon and\u002For anesthesiologist\n* Patients deemed not suitable for the IAT follow-up protocol by any member of the multi-disciplinary IAT care team\n* Any alcohol or tobacco use within 6 months of study enrollment\n* Financial, logistic, or insurance constraints preventing adequate and timely pre-operative evaluation, case scheduling, or post-operative monitoring\u002Ffollow-up\n* Pregnant individuals are excluded from this study because invasive abdominal surgical procedures such as pancreatectomy have the known potential to cause pregnancy loss",{"count":5,"type":21},[115,116],"This phase I\u002FII trial assesses the safety and effectiveness of total pancreatectomy with islet cell autotransplantation for the treatment of patients with long-term pancreatic inflammation (chronic pancreatitis) and non-cancerous (benign) pancreatic tumors. Total removal of the pancreas (pancreatectomy) can be used to treat chronic pancreatitis, but it may result in diabetes. An islet cell autotransplantation involves removing cells from a patient's pancreas (the islet cells) and infusing them into the liver. Islet cells are responsible for producing hormones like insulin, reducing the occurrence of diabetes in patients undergoing total pancreatectomy. Total pancreatectomy with autologous islet cell transplant is an accepted and Food and Drug Administration-approved treatment for patients with chronic pancreatitis. However, patients with chronic pancreatitis and pancreatic tumors have historically not been candidates for this procedure due to concerns of spreading potentially cancerous cells to other parts of the body. This clinical trial evaluates the safety and effectiveness of this treatment in patients with chronic pancreatitis and benign pancreatic tumors.",[173,62,28],"Benign Pancreatic Neoplasm","2025-11-21",{"date":176,"type":41},"2025-11-25",{"date":178,"type":21},"2026-07-01",{"date":180,"type":21},"2030-07-01",{"name":182,"class":48},"OHSU Knight Cancer Institute",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":198,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":207,"leadSponsor":209,"locationsCount":49},"100606097","phase-2-smoking-cessation-trial-in-recurrent-acute-pancreatitis-and-chronic-pancreatitis-100606097","NCT07171112","Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis","Smoking Cessation Treatment Escalation Among Patients With Recurrent Acute Pancreatitis and Chronic Pancreatitis","Inclusion Criteria\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 18 or older\n* Diagnosed with either recurrent acute pancreatitis or chronic pancreatitis as defined by the American Pancreatic Association:\n\n  o Chronic Pancreatitis (any of the following): i. Moderate\u002Fmarked pancreas imaging morphology (i.e. ductal and parenchymal abnormalities ii. Pancreatic calcifications iii. Histologic confirmation\n\n  o Recurrent Acute Pancreatitis: i. Two or more documented attacks of acute pancreatitis, separated by 3 months from one another, defined by at least 2 of the following 3:\n  1. amylase or lipase values, or both, that are greater than 3 times the upper limit of normal values\n  2. characteristic cross-sectional imaging\n  3. typically upper abdominal pain according to the revised Atlanta classification\n* Currently smoking ≥ 5 cigarettes\u002Fday\n* Explicitly express a desire to quit within 30 days\n* Ability to take oral medication and be willing to adhere to the study intervention regimen\n* Willing and able to comply with trial protocol and follow-up\n\nExclusion Criteria\n\n* Age \\\u003C 18 years\n* Ongoing acute pancreatitis or prior episode of pancreatitis in previous 30 days\n* No desire to quit smoking\n* Currently undergoing smoking cessation intervention (i.e. nicotine replacement therapy, varenicline, counseling, bupropion).\n* Known allergic reactions to varenicline or bupropion SR\n* History of seizures\n* History of an eating disorder (anorexia or bulimia)\n* Closed head trauma with any loss of consciousness or amnesia in the last 5 year\n* Ever history of closed head trauma with \\> 30 minutes of loss of consciousness or amnesia or resulting in skull fracture or subdural hematoma\u002Fbrain contusion\n* Ever history of alcohol withdrawal\n* Ever history of chronic kidney disease (creatine clearance \\\u003C 30 mL\u002Fminute)\n* Liver impairment (i.e. history of cirrhosis) with aminotransferase elevation ≥ 2 times the upper limit of normal and\u002For alkaline phosphatase elevation ≥ 2 times the upper limit of normal.\n* History of bipolar disorder or psychosis\n* Ongoing or recent use (prior 14 days) of any monoamine oxidase inhibitors (isocarboxazid, phenelzine, tranylcypromine, selegiline).\n* Regular use of potent CYP2B6 inhibitors (i.e. clopidogrel, ticlopidine)\n* Regular use of CYP2D6 substrates with narrow therapeutic indices (e.g. flecainide, propafenone, tricyclic antidepressants such as nortriptyline, thioridazine, vinblastine)\n* History of acute angle closure glaucoma\n* Meet criteria for depression as assessed by the Center for Epidemiologic Studies - Depression (CES-D) with a score of 16 or higher.\n* Psychiatric hospitalization within 1 year of screening\n* Participants who have a score of 3 or higher on the Columbus-Suicide Severity Rating Scale (C-SSRS) at enrollment or during any of the study assessments will be excluded\n* Unable to provide consent for self Incarcerated\n* Pregnant females. All female patients of childbearing potential must have a negative pregnancy test and must agree to use highly effective (failure rate \\\u003C1%) contraception during participation in the study.",{"count":191,"type":21},45,[116],"The purpose of this research is to assess the effectiveness of two treatment strategies for smoking cessation in patients with acute recurrent pancreatitis or chronic pancreatitis who smoke cigarettes. All participants will receive varenicline, a commonly used medication that helps people stop smoking, at its standard dose. For those who are unable to stop smoking after 6 weeks of treatment, they will be randomly selected to either 1) increase their dose of varenicline, 2) combine varenicline with bupropion (another medication that helps with smoking cessation) or continue on the standard dose of varenicline. At the end of 12 weeks of treatment, participants will be asked if they have stopped smoking with confirmation done by measuring carbon monoxide levels in their breath.",[195,196,28,197],"Pancreatitis, Chronic","Pancreatitis, Acute","Smoking (Tobacco) Addiction",[199,200,33,201,202],"Smoking cessation","chronic pancreatitis","varenicline","bupropion","2025-11-06",{"date":205,"type":41},"2025-11-10",{"date":203,"type":41},{"date":208,"type":21},"2028-10-01",{"name":210,"class":48},"Mayo Clinic",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":78},"100535537","phase-2-evaluation-of-pirfenidone-as-a-novel-therapeutic-strategy-against-recurrent-acute-pancreatitis-100535537","NCT06253117","Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.","PirfenidoneRAP","A- Inclusion Criteria:\n\n1. Patients 18 - 85 years of age\n2. Two or more documented attacks of acute pancreatitis, separated by 3 months from one another, defined by at least 2 of the following 3:\n\n   1. amylase or lipase values, or both, that are greater than 3 times the upper limit of normal values\n   2. characteristic cross-sectional imaging\n   3. typical upper abdominal pain according to the revised Atlanta classification28\n3. Drug\u002Fplacebo treatment to start\n\n   1. Mild AP Patient is discharged out of the hospital 30 days after diagnosis of mild AP\n   2. Moderate Severe or Severe AP Patient is discharged out of hospital Intra-abdominal collections are either resolved on imaging, or are improving and asymptomatic (VAS Pain score ≤3 \\[with or without pain medication\\], vomiting ≤once a week, tolerating light diet, and no fever and chills) and do not warrant any intervention (per treating physician)\n4. Ability to understand and the willingness to sign a written informed consent document and medical release\n5. Willing and able to comply with trial protocol and follow up\n6. 2nd AP episode despite correction of the AP etiology (if identified) after the 1st episode as follows i. Patients with biliary pancreatitis who have undergone cholecystectomy, with or without ERCP (if indicated) ii. Patients with hypertriglyceridemia induced pancreatitis who have serum triglyceride levels below 400 while on medication management iii. Patients with medication induced AP developing a 2nd AP episode despite stopping the culprit medication\n\nB- Exclusion Criteria:\n\n1. Age \\\u003C 18 or \\> 85 years.\n2. Body weight \\> 200 kg.\n3. Ongoing AP (in right clinical situation defined by pain\\>3, vomiting ≥once a week, fever or chills, not tolerating light diet) or diagnosis of AP in previous 30 days.\n4. Diagnosis of chronic pancreatitis, one of the following\n\n   1. Ductal stricture, calcification and\u002For atrophy, as seen on CT scan\u002FMRI\n   2. 5 or more of the 9 EUS criteria used to diagnose CP\n5. Known hypersensitivity to Pirfenidone.\n6. AST\u002FALT \\> 3 times the upper normal limit.\n7. Alkaline phosphatase \\>2.5 times the upper normal limit.\n8. Bilirubin higher than upper normal limit.\n9. Moderate to severe heart failure and\u002For coronary heart disease (New York Heart Association (NYHA) Functional Class III\u002FIV).\n10. On home oxygen or home mechanical ventilation.\n11. Advanced liver disease as defined by Child-Pugh cirrhosis B or C.\n12. Paralytic ileus or significant nausea and vomiting preventing administration of light diet.\n13. Chronic diarrhea (\\>6 months, 3 or more stools\u002Fday-Clinically not appearing to be steatorrhea \\[fecal fat if done less than 15 g per day and fecal elastase if done more than 100\\].Active cancer (on chemotherapy, radiation or treatment of cancer at the time of enrollment) or cancer free \\\u003C3 years (non-melanoma skin cancer are not a contraindication)\n14. Known cancer that is end-stage with ongoing palliative care or for which palliative care is appropriate.\n15. Known history of infective hepatitis (Hepatitis B or C)\\[can enroll if treatment and cure is documented\\]\n16. Ongoing photosensitivity and rash.\n17. Known live vaccines or therapeutic infectious agents within one month of admission.\n18. Known pregnancy or lactation at the time of admission.\n19. Women of childbearing potential who are not on oral or injectable contraceptives or IUDs, and do not consent to adequate contraception while on, and for 90 days after the administration of the drug\u002Fplacebo.\n20. Known to be currently participating in a trial testing any investigational medicinal product or participation in a clinical study involving a medicinal product in the last three months.\n21. Problematic pattern of alcohol use or moderate to severe alcohol use disorder (Appendix 2)\n22. Substance use disorder (except recreational or medicinal use of marijuana) \\[if patient underwent and completed a rehab program, has not used substances for at least one year, and has an adequate support system, they may be enrolled\\]\n23. Family or personal history of long QT syndrome (\\> 500 msec).\n24. Strong CYP1A2 inhibitors (e.g., fluvoxamine, enoxacin) or moderate CYP1A2 Inhibitors (e.g., ciprofloxacin).\n25. Renal disease with GFR \\\u003C 30.\n26. Any condition other than above that, in the opinion of the investigator, is likely to result in the death of the patient within the next 2 years.\n27. Any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of Pirfenidone.","85 Years",{"count":220,"type":21},60,[116],"This clinical will evaluate the safety, tolerability and early efficacy of pirenidone in patients with recurrent acute pancreatitis.",[28],"2025-10-09",{"date":226,"type":41},"2025-10-14",{"date":228,"type":41},"2024-06-27",{"date":230,"type":21},"2028-09-01",{"name":232,"class":48},"University of Alabama at Birmingham",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":49},"100544093","efficacy-of-ercp-in-the-diagnosis-and-treatment-of-idiopathic-recurrent-acute-pancreatitis-100544093","NCT06364397","Efficacy of ERCP in the Diagnosis and Treatment of Idiopathic Recurrent Acute Pancreatitis","Efficacy of ERCP in the Diagnosis and Treatment of Idiopathic Recurrent Acute Pancreatitis: a Randomized Controlled Trial","ESPRIT","Inclusion Criteria:\n\n1. Aged 18 to 70 years.\n2. Patients diagnosed with IRAP:\n\n   1. Previously experienced 2 or more distinct episodes of acute pancreatitis (AP) with complete resolution between each episode, and absence of irreversible structural and functional changes in pancreas. The diagnosis of AP is based on the Atlanta criteria and is documented in the medical record.\n   2. The etiology of RAP remains undetermined after routine clinical investigations, including history, laboratory examination, imaging examination (CT, MRI\u002FMRCP, EUS). Patients who still have AP episodes after elimination of the etiology also be included.\n3. At least 1 episode of AP one year prior to enrollment.\n4. Consent to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Prior sphincter intervention.\n2. Not recovered from prior AP attack.\n3. Prior pancreatic surgery.\n4. Contraindications to ERCP.\n5. Major mental illness or serious health problems that are not suitable for participation in the study.\n6. Pregnancy or plan for pregnancy within 12 months of enrollment.\n7. Other conditions that inappropriate to participant in the study.","70 Years",{"count":243,"type":21},158,[245],"NA","The goal of this clinical trial is to learn if endoscopic retrograde cholangiopancreatography (ERCP) works to treat idiopathic recurrent pancreatitis (IRAP) in adults. It also clarify the efficacy of ERCP in the diagnosis of IRAP. The main questions it aims to answer are:\n\nDoes ERCP reduce the frequency of pancreatitis episodes in IRAP patients? Does ERCP contribute to identify the etiology of IRAP patients?\n\nParticipants will be randomly allocated to receive ERCP (pancreatic sphincterotomy and pancreatic stent placement) or conservative treatment and be followed for 1 year.",[28],[249,250,251,252],"Recurrent acute pancreatitis","Idiopathic","ERCP","Sphincterotomy","2024-07-11",{"date":255,"type":41},"2024-07-12",{"date":257,"type":41},"2024-07-01",{"date":259,"type":21},"2026-05",{"name":261,"class":48},"Changhai Hospital",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":89,"phases":4,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":49},"100543387","natural-course-and-therapeutic-effect-of-recurrent-acute-pancreatitis-100543387","NCT06355206","Natural Course and Therapeutic Effect of Recurrent Acute Pancreatitis","Natural Course and Therapeutic Effect of Recurrent Acute Pancreatitis: a Prospective Cohort Study","NACRE","Inclusion Criteria:\n\n* Patients with recurrent acute pancreatitis.\n\nExclusion Criteria:\n\n* Unwilling or unable to provide consent.",{"count":271,"type":21},2000,"The goal of this observational cohort study is to learn about the etiology, natural course, therapeutic effect and outcome of recurrent acute pancreatitis patients. The main question it aims to answer is:\n\nDoes endoscopic intervention, surgery or conservative treatment reduce the recurrence of acute pancreatitis? What are the risk factors affecting the recurrence of acute pancreatitis?\n\nPatients will be closely followed and clinical information will be recorded.",[274,28],"Cohort Study",[33,276,277],"natural course","therapeutic effect","2024-05-07",{"date":280,"type":41},"2024-05-09",{"date":282,"type":41},"2024-04-22",{"date":284,"type":21},"2034-12",{"name":261,"class":48},{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":17,"minAge":293,"maxAge":111,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":49},"100530349","the-effect-of-aspirin-on-recurrent-acute-pancreatitis-100530349","NCT06185621","The Effect of Aspirin on Recurrent Acute Pancreatitis","The Effect of 100mg Aspirin on Recurrent Acute Pancreatitis: a Prospective Cohort Study","Inclusion Criteria:\n\n* Patients with with recurrent acute pancreatitis\n\nExclusion Criteria:\n\n* Less than 2 episodes of acute pancreatitis in the past year\n* Latrogenic AP (pancreatitis due to endoscopic retrograde cholangiopancreatography, surgery, or after other invasive treatment). Iatrogenic pancreatitis will not count as an episode of recurrent pancreatitis\n* Previous allergy to Non-Steroid Anti-inflammatory Drugs (NSAIDs)\n* Regularly taking aspirin or other NSAIDs \\>3 doses per week\n* Contradictions for the medications of NSAIDs, including Active peptic ulcer disease or gastrointestinal hemorrhage within 3 months or previous peptic ulcer, history of significant hepatic or renal disease, platelet count less than 100X10\\^9\u002FL or international normalized ratio (INR) \\>1.5)\n* Biliary stones\n* Receiving endoscopic sphincterotomy and\u002For pancreatic stent placement and\u002For cholecystectomy and\u002For pancreatic surgery after the latest pancreatitis or planning to undergo one of those interventions within preceding 2 years\n* Patients with the level of serum triglycerides of \\>5.65 mmol\u002FL and did not receive regular lipid-lowering therapy\n* Primary hyperparathyroidism has been well-treated after last episode of pancreatitis and recruitment or will be operated in \\\u003C2 years\n* Patients with previously heavy alcohol consumption (50g\u002Fday for men, 40g\u002Fday for women) and have not quit drinking, or have significant withdrawal symptoms\n* Pregnant or breastfeeding patients\n* Inability to give informed consents","14 Years",{"count":295,"type":21},23,[245],"Recurrent acute pancreatitis (RAP) was defined as two or more occurrences of acute pancreatitis, which was associated with higher percentages of morbidities and mortalities, lower patients' life quality and increased health-care costs. Current interventions, including cholecystectomy and abstain from drinking were reported to be effective methods for preventing the recurrences of biliary and alcoholic etiologies, respectively. However, there were no effective preventions for other etiologies, such as idiopathic etiologies. Non-steroid anti-inflammatory drugs (NSAIDs), including indomethacin, diclofenac and aspirin could inhibiting the inflammatory cascade of pancreatitis. In this study, we aimed at exploring the effects of 100mg aspirin on reducing the occurrences of recurrent acute pancreatitis.",[28,299,300],"Prevention","Aspirin","2023-12-15",{"date":303,"type":41},"2023-12-29",{"date":305,"type":41},"2023-11-01",{"date":307,"type":21},"2026-11-01",{"name":309,"class":48},"Air Force Military Medical University, China",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":320,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":49},"100412172","preventing-the-recurrence-of-acute-pancreatitis-by-alcohol-and-smoking-cessation-100412172","NCT04647097","Preventing the Recurrence of Acute Pancreatitis by Alcohol and Smoking Cessation","Recurrent Acute Pancreatitis Prevention by the Elimination of Alcohol and Cigarette Smoking (REAPPEAR): Protocol of a Randomized Controlled Trial and a Cohort Study","REAPPEAR","Inclusion criteria:\n\n* Patient hospitalized with alcohol-induced AP (defined by the revised Atlanta criteria 38)\n* Every day smoker (defined as an adult patient who smoked at least 100 cigarettes in his or her lifetime, and now smokes on a daily basis; as per the CDC definition), with at least 1-year history of smoking\n* Aged 18-80 years\n* Provided written informed consent\n* Willing to participate in the intervention in every three months\n\nExclusion criteria:\n\n* Possible etiologies for AP other than alcohol (eg. gallstone-related, hypertriglyceridemia above 11.5 mM 40-42, hypercalcemia, viral infection) if the etiological cannot be terminated during the index admission (lack of same admission cholecystectomy, familiar hypertrygliceridemia) and cases with combined etiological factors will be excluded\n* Untreated, decompensated or severe mMajor psychiatric illnesses (e.g. schizophrenia, bipolar disorder, dementia)\n* Currently taking part in a smoking cessation program\n* Undergoing active or palliative treatment for malignancy\n* Pregnancy, breastfeeding\n* Life expectancy is less than two years\n* Didn't agreed to participate\n* Other",{"count":319,"type":21},364,[245],"Recurrence of acute pancreatitis (AP) is often facilitated by regular alcohol consumption and smoking. An applied lifestyle intervention focusing on the cessation of alcohol consumption and smoking might prevent the recurrence of AP. REAPPEAR Study is a randomized controlled trial and a cohort study focusing on the efficacy of the lifestyle intervention and the effect of quitting alcohol and smoking respectively.",[323,28],"Acute Pancreatitis",[325,33,326,327,328],"acute pancreatitis","smoking","alcohol","lifestyle intervention","2023-04-25",{"date":331,"type":41},"2023-04-26",{"date":333,"type":41},"2022-03-01",{"date":335,"type":21},"2028-06-30",{"name":337,"class":48},"University of Pecs"]